Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection
Charing C. N. Chong(National University of Singapore), Paul B.S. Lai(Chinese University of Hong Kong), John Wong(Chinese University of Hong Kong), Hon‐Ting Lok(Chinese University of Hong Kong), A. Fung(Chinese University of Hong Kong), Kit‐Fai Lee(Chinese University of Hong Kong), Simon C.H. Yu(National Yang Ming Chiao Tung University), Philip J. Johnson(Prince of Wales Hospital), Stephen L. Chan(Chinese University of Hong Kong), Anthony W.H. Chan(Chinese University of Hong Kong), Cheuk-Man Chu(Chinese University of Hong Kong), Anthony Fong(Chinese University of Hong Kong), Yue S. Cheung(Chinese University of Hong Kong)
Cited by 42
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k